Colorectal Cancer

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.

Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.

Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.

Rahmi Oklu, MD, PhD, discusses various approaches physicians use to treat patients who have CRC with liver metastases.

Axel Grothey, MD, discusses frontline therapy and maintenance strategies for patients with metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

Arturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.